• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
In silico analyses of the tumor microenvironment highlight tumoral inflammation, a Th2 cytokine shift and a mesenchymal stem cell-like phenotype in advanced in basal cell carcinomas.基底细胞癌晚期肿瘤微环境的计算机模拟分析突出了肿瘤炎症、Th2细胞因子转变和间充质干细胞样表型。
J Cell Commun Signal. 2020 Jun;14(2):245-254. doi: 10.1007/s12079-020-00563-6. Epub 2020 Mar 21.
2
Comparison of the Basal Cell Carcinoma (BCC) Tumour Microenvironment to Other Solid Malignancies.基底细胞癌(BCC)肿瘤微环境与其他实体恶性肿瘤的比较。
Cancers (Basel). 2023 Jan 2;15(1):305. doi: 10.3390/cancers15010305.
3
A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.对刺猬信号通路及维莫德吉在基底细胞癌治疗中作用的全面综述。
Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Epub 2015 Mar 17.
4
Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.晚期基底细胞癌患者接受 Hedgehog 通路抑制剂维莫德吉治疗的扩大准入研究。
J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012. Epub 2013 Nov 1.
5
Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials.维莫德吉治疗基底细胞痣综合征患者的安全性和有效性:两项试验的汇总分析
Orphanet J Rare Dis. 2016 Sep 1;11(1):120. doi: 10.1186/s13023-016-0506-z.
6
Local immune response in cutaneous basal cell carcinoma.皮肤基底细胞癌中的局部免疫反应。
Dan Med J. 2017 Oct;64(10).
7
Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.维莫德吉治疗基底细胞癌:ERIVANCE BCC试验的结果及意义
Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50.
8
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma.局部晚期基底细胞癌中维莫德吉内在耐药的频率和基因组方面。
Clin Cancer Res. 2022 Apr 1;28(7):1422-1432. doi: 10.1158/1078-0432.CCR-21-3764.
9
Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment.人类基底细胞癌在以Th2为主导的微环境中与Foxp3 + T细胞相关。
J Invest Dermatol. 2007 Oct;127(10):2391-8. doi: 10.1038/sj.jid.5700884. Epub 2007 May 17.
10
Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC.Erivance 关键性基底细胞癌(BCC)研究:维莫德吉治疗晚期 BCC 的疗效和安全性 12 个月更新。
J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8. doi: 10.1016/j.jaad.2015.03.021.

引用本文的文献

1
Immunotherapy in Basal Cell Carcinoma.基底细胞癌的免疫疗法
J Clin Med. 2024 Sep 26;13(19):5730. doi: 10.3390/jcm13195730.
2
Therapeutic Advances in Advanced Basal Cell Carcinoma.晚期基底细胞癌的治疗进展
Cancers (Basel). 2024 Sep 4;16(17):3075. doi: 10.3390/cancers16173075.
3
Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment-A Cross-Sectional Study.皮肤基底细胞癌和鳞状细胞癌中的浸润 T 细胞:Th1 优势的全球格局与 Th17 富集——一项横断面研究。
Cells. 2024 Jun 3;13(11):964. doi: 10.3390/cells13110964.
4
Gene-Environment Analyses in a UK Biobank Skin Cancer Cohort Identifies Important SNPs in DNA Repair Genes That May Help Prognosticate Disease Risk.在英国生物银行皮肤癌队列中进行的基因-环境分析确定了 DNA 修复基因中的重要 SNP,这些 SNP 可能有助于预测疾病风险。
Cancer Epidemiol Biomarkers Prev. 2023 Nov 1;32(11):1599-1607. doi: 10.1158/1055-9965.EPI-23-0545.
5
National trends in incidence and geographic distribution of melanoma and keratinocyte carcinoma in the Russian Federation.俄罗斯联邦黑色素瘤和角质形成细胞癌的发病率及地理分布的全国趋势。
Front Med (Lausanne). 2023 Jul 20;10:1188038. doi: 10.3389/fmed.2023.1188038. eCollection 2023.
6
Ectopically Expressed Meiosis-Specific Cancer Testis Antigen HORMAD1 Promotes Genomic Instability in Squamous Cell Carcinomas.异位表达的减数分裂特异性肿瘤睾丸抗原 HORMAD1 促进鳞状细胞癌的基因组不稳定性。
Cells. 2023 Jun 14;12(12):1627. doi: 10.3390/cells12121627.
7
Review of the Tumor Microenvironment in Basal and Squamous Cell Carcinoma.基底细胞癌和鳞状细胞癌的肿瘤微环境综述
Cancers (Basel). 2023 Apr 25;15(9):2453. doi: 10.3390/cancers15092453.
8
Comparison of the Basal Cell Carcinoma (BCC) Tumour Microenvironment to Other Solid Malignancies.基底细胞癌(BCC)肿瘤微环境与其他实体恶性肿瘤的比较。
Cancers (Basel). 2023 Jan 2;15(1):305. doi: 10.3390/cancers15010305.
9
The Use of Retinoids for the Prevention and Treatment of Skin Cancers: An Updated Review.类视黄醇在皮肤癌的预防和治疗中的应用:最新综述。
Int J Mol Sci. 2022 Oct 20;23(20):12622. doi: 10.3390/ijms232012622.
10
The Contributions of Cancer-Testis and Developmental Genes to the Pathogenesis of Keratinocyte Carcinomas.癌-睾丸基因和发育基因对角化细胞癌发病机制的作用
Cancers (Basel). 2022 Jul 26;14(15):3630. doi: 10.3390/cancers14153630.

本文引用的文献

1
Patterns of Immune Infiltration in HNC and Their Clinical Implications: A Gene Expression-Based Study.头颈部肿瘤的免疫浸润模式及其临床意义:一项基于基因表达的研究
Front Oncol. 2019 Dec 4;9:1285. doi: 10.3389/fonc.2019.01285. eCollection 2019.
2
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME).多他司他汀通过调节肿瘤免疫微环境(TIME)有利于免疫治疗反应。
J Immunother Cancer. 2019 Nov 8;7(1):294. doi: 10.1186/s40425-019-0745-3.
3
A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition.细胞身份转换使残留的基底细胞癌能够在 Hedgehog 通路抑制下存活。
Nature. 2018 Oct;562(7727):429-433. doi: 10.1038/s41586-018-0596-y. Epub 2018 Oct 8.
4
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy.一个慢周期 LGR5 肿瘤细胞群介导了基底细胞癌治疗后的复发。
Nature. 2018 Oct;562(7727):434-438. doi: 10.1038/s41586-018-0603-3. Epub 2018 Oct 8.
5
Gene expression profiling and immune cell-type deconvolution highlight robust disease progression and survival markers in multiple cohorts of CTCL patients.基因表达谱分析和免疫细胞类型反卷积揭示了蕈样肉芽肿患者多个队列中显著的疾病进展和生存标志物。
Oncoimmunology. 2018 May 31;7(8):e1467856. doi: 10.1080/2162402X.2018.1467856. eCollection 2018.
6
Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis.索那替尼抑制剂治疗基底细胞癌的疗效、安全性及比较:系统评价和荟萃分析。
J Am Acad Dermatol. 2018 Dec;79(6):1089-1100.e17. doi: 10.1016/j.jaad.2018.07.004. Epub 2018 Jul 10.
7
Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples.在富含调节性T细胞的患者肿瘤样本中鉴定与良好临床特征相关的免疫基因表达特征。
NPJ Genom Med. 2018 Jun 13;3:14. doi: 10.1038/s41525-018-0054-7. eCollection 2018.
8
Understanding the tumor immune microenvironment (TIME) for effective therapy.理解肿瘤免疫微环境(TIME)以实现有效的治疗。
Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23.
9
Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma.健康肝脏与肝癌之间免疫细胞景观的差异。
Sci Rep. 2018 Apr 18;8(1):6220. doi: 10.1038/s41598-018-24437-5.
10
xCell: digitally portraying the tissue cellular heterogeneity landscape.xCell:数字化描绘组织细胞异质性景观。
Genome Biol. 2017 Nov 15;18(1):220. doi: 10.1186/s13059-017-1349-1.

基底细胞癌晚期肿瘤微环境的计算机模拟分析突出了肿瘤炎症、Th2细胞因子转变和间充质干细胞样表型。

In silico analyses of the tumor microenvironment highlight tumoral inflammation, a Th2 cytokine shift and a mesenchymal stem cell-like phenotype in advanced in basal cell carcinomas.

作者信息

Lefrançois Philippe, Xie Pingxing, Gunn Scott, Gantchev Jennifer, Villarreal Amelia Martínez, Sasseville Denis, Litvinov Ivan V

机构信息

Division of Dermatology, McGill University Health Centre, Rm. E02.6236, 1001 Decarie Blvd, Montréal, Québec, H4A 3J1, Canada.

出版信息

J Cell Commun Signal. 2020 Jun;14(2):245-254. doi: 10.1007/s12079-020-00563-6. Epub 2020 Mar 21.

DOI:10.1007/s12079-020-00563-6
PMID:32198729
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7272519/
Abstract

Basal Cell Carcinoma (BCC) represents the most common form of all cancers. BCC is characteristically surrounded by a fibromyxoid stroma. Previous studies have suggested a shift towards a Th2 response, an increase in T regulatory lymphocytes and the presence of cancer-associated fibroblasts in the BCC tumor microenvironment. In this study, we aimed to further characterize the BCC tumor microenvironment in detail by analyzing BCC RNA-Sequencing data and correlating it with clinically-relevant features via in silico RNA deconvolution. Using immune cell type deconvolution by CIBERSORT, we have identified a brisk lymphocytic infiltration, and more abundant macrophages in BCC tumors compared to normal skin. Using cell type enrichment by xCell, we confirmed the observed immune infiltration in BCC tumors and compared them to normal skin. We observed a shift towards Th2 immunity in advanced and vismodegib-resistant tumors. Tumoral inflammation induced by macrophage activity was associated with advanced BCCs, while lymphocytic infiltration was most significant in non-advanced tumors, likely related to an adaptive anti-tumoral response. In advanced and vismodegib-resistant BCCs, mesenchymal stem cell-like properties were observed. Particularly in vismodegib-resistant BCCs, fibroblasts and adipocytes were found at high number, which ultimately may contribute to the decreased drug delivery to the tumor. In conclusion, this study has revealed notable BCC tumor microenvironment findings associated with important clinical features. Microenvironment-altering agents may be used locally for "routine" BCCs and systematically for advanced or resistant BCCs.

摘要

基底细胞癌(BCC)是所有癌症中最常见的形式。BCC的特征是被纤维黏液样基质包围。先前的研究表明,BCC肿瘤微环境向Th2反应转变、调节性T淋巴细胞增加以及存在癌症相关成纤维细胞。在本研究中,我们旨在通过分析BCC RNA测序数据并通过计算机RNA反卷积将其与临床相关特征相关联,进一步详细表征BCC肿瘤微环境。使用CIBERSORT进行免疫细胞类型反卷积,我们发现与正常皮肤相比,BCC肿瘤中有活跃的淋巴细胞浸润和更丰富的巨噬细胞。使用xCell进行细胞类型富集,我们证实了在BCC肿瘤中观察到的免疫浸润,并将其与正常皮肤进行了比较。我们在晚期和维莫德吉耐药肿瘤中观察到向Th2免疫的转变。巨噬细胞活性诱导的肿瘤炎症与晚期BCC相关,而淋巴细胞浸润在非晚期肿瘤中最为显著,这可能与适应性抗肿瘤反应有关。在晚期和维莫德吉耐药的BCC中,观察到间充质干细胞样特性。特别是在维莫德吉耐药的BCC中,发现大量的成纤维细胞和脂肪细胞,这最终可能导致肿瘤药物递送减少。总之,本研究揭示了与重要临床特征相关的显著BCC肿瘤微环境发现。改变微环境的药物可局部用于“常规”BCC,全身用于晚期或耐药BCC。